JP2008509149A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008509149A5 JP2008509149A5 JP2007524981A JP2007524981A JP2008509149A5 JP 2008509149 A5 JP2008509149 A5 JP 2008509149A5 JP 2007524981 A JP2007524981 A JP 2007524981A JP 2007524981 A JP2007524981 A JP 2007524981A JP 2008509149 A5 JP2008509149 A5 JP 2008509149A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- agent according
- human
- injection
- blood vessel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59944904P | 2004-08-06 | 2004-08-06 | |
| PCT/US2005/027712 WO2006017650A2 (en) | 2004-08-06 | 2005-08-05 | Iron chelators for treating radiocontrast-associated renal dysfunction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011274990A Division JP2012102110A (ja) | 2004-08-06 | 2011-12-15 | 造影剤の注入を受けるヒトの処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008509149A JP2008509149A (ja) | 2008-03-27 |
| JP2008509149A5 true JP2008509149A5 (https=) | 2011-02-24 |
Family
ID=35539425
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007524981A Pending JP2008509149A (ja) | 2004-08-06 | 2005-08-05 | 造影剤の注入を受けるヒトの処置方法 |
| JP2011274990A Withdrawn JP2012102110A (ja) | 2004-08-06 | 2011-12-15 | 造影剤の注入を受けるヒトの処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011274990A Withdrawn JP2012102110A (ja) | 2004-08-06 | 2011-12-15 | 造影剤の注入を受けるヒトの処置方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20060127315A1 (https=) |
| EP (1) | EP1776118A2 (https=) |
| JP (2) | JP2008509149A (https=) |
| AU (1) | AU2005271455A1 (https=) |
| CA (1) | CA2576190A1 (https=) |
| WO (1) | WO2006017650A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080004507A1 (en) * | 2004-10-27 | 2008-01-03 | E-Z-Em, Inc. | Data collection device, system, method, and computer program product for collecting data related to the dispensing of contrast media |
| WO2008057534A2 (en) * | 2006-11-07 | 2008-05-15 | University Of Vermont And State Agricultural College | Methods and compositions for organ protection |
| US20080138440A1 (en) * | 2006-11-29 | 2008-06-12 | Cormedix Inc. | Methods of diagnosing and alleviating gadolinium toxicity |
| MX2017008959A (es) | 2015-01-07 | 2018-05-17 | Nottingham Univ Hospitals Nhs Trust | Biomarcadores relacionados con la funcion del riñon y metodos que involucran su uso. |
| JP2018528207A (ja) * | 2015-08-31 | 2018-09-27 | ザ ユニバーシティー オブ アデレード | 鉄キレート剤および非鉄ポルフィリンを含む、微生物感染症を予防および／または処置する方法および製品 |
| MD3684344T2 (ro) | 2017-10-25 | 2025-09-30 | Chiesi Farm Spa | Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora |
| US12016851B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| US12016850B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1100388A (en) * | 1986-12-29 | 1988-07-27 | The Administrators Of The Tulane Eductional Fund | Protection against aminoglycoside-induced nephrotoxicity |
| US5091180A (en) * | 1987-11-20 | 1992-02-25 | Administrators Of The Tulane Educational Fund | Protection against rhabdomyolysis-induced nephrotoxicity |
| US6933104B1 (en) * | 1999-04-23 | 2005-08-23 | Shiva Biomedical, Llc | Diagnosis and treatment of human kidney diseases |
| DE60039756D1 (de) * | 1999-04-23 | 2008-09-18 | Shiva Biomedical Llc | Diagnostisches verfahren für nierenkrankheiten in menschen |
| AUPQ262499A0 (en) * | 1999-09-02 | 1999-09-23 | University Of Queensland, The | Novel iron chelators |
| US6509380B1 (en) * | 2001-12-14 | 2003-01-21 | Marshall University Research Corporation | Method of treating iron overload with acetaminophen |
-
2005
- 2005-08-05 US US11/198,931 patent/US20060127315A1/en not_active Abandoned
- 2005-08-05 JP JP2007524981A patent/JP2008509149A/ja active Pending
- 2005-08-05 WO PCT/US2005/027712 patent/WO2006017650A2/en not_active Ceased
- 2005-08-05 AU AU2005271455A patent/AU2005271455A1/en not_active Abandoned
- 2005-08-05 CA CA002576190A patent/CA2576190A1/en not_active Abandoned
- 2005-08-05 EP EP05779279A patent/EP1776118A2/en not_active Withdrawn
-
2008
- 2008-01-28 US US12/010,656 patent/US20080293779A1/en not_active Abandoned
-
2011
- 2011-03-29 US US13/074,811 patent/US20120053212A1/en not_active Abandoned
- 2011-12-15 JP JP2011274990A patent/JP2012102110A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pomier-Layrargues et al. | Octreotide in Hepatorenal Syndrome: A Randomized, Double–Blind, Placebo–Controlled, Crossover Study | |
| Ytrebø et al. | L‐ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure | |
| Arroyo et al. | Treatment of ascites in cirrhosis: diuretics, peritoneovenous shunt, and large-volume paracentesis | |
| JP2019505585A (ja) | ２−ブロモ−１−（３，３−ジニトロアゼチジン−１−イル）エタノンの静脈内投与のための組成物および方法 | |
| AU2017256774B2 (en) | Semaglutide in cardiovascular conditions | |
| JP2008509149A5 (https=) | ||
| Doria et al. | Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus | |
| JP2012102110A (ja) | 造影剤の注入を受けるヒトの処置方法 | |
| Gines et al. | Pharmacological treatment of hepatorenal syndrome | |
| Faltlhauser et al. | Use of hemoadsorption in a case of severe hepatic failure and hyperbilirubinemia | |
| JP3336331B2 (ja) | 新生内膜形成、再狭窄、および動脈硬化の予防および処置のための薬剤としてのデスアスパラギン酸アンジオテンシンｉを使用する薬学的組成物 | |
| Kokot et al. | Drug-induced abnormalities of potassium metabolism | |
| Maffei et al. | Refractory Takayasu arteritis successfully treated with infliximab. | |
| CN101686953A (zh) | 4-(硝基氧)-丁基-(s)-2-(6-甲氧基-2-萘基)-丙酸酯在治疗疼痛和炎症中的用途 | |
| Peters et al. | Renal and cardiovascular effects of irbesartan in dialysis patients-a randomized controlled trial protocol (SAFIR study) | |
| Clemmesen et al. | The effect of increasing blood pressure with dopamine on systemic, splanchnic, and lower extremity hemodynamics in patients with acute liver failure | |
| Schou et al. | Angiotensin II attenuates the natriuresis of water immersion in humans | |
| Ortíz et al. | Renal and pressor effects of aminoguanidine in cirrhotic rats with ascites. | |
| Nishimoto et al. | Acute intracranial hypertension due to occlusion of the brachiocephalic vein in a patient undergoing hemodialysis. | |
| Bollerup et al. | Changes of glomerular filtration rate and renal plasma flow following intravenous bumetanide in organic heart disease | |
| Arroyo et al. | Hepatorenal syndrome in cirrhosis: clinical features, diagnosis, and management | |
| Fitzgerald et al. | Systemic hemodynamic responses to chronic angiotensin II infusion into the renal artery of dogs | |
| Furlan et al. | Special aspects in the treatment of severe hemispheric brain infarction | |
| Razzaghi et al. | A comparative study on the effect of lidocaine and furosemide on urinary output and graft function after renal transplantation | |
| WO2026090251A1 (en) | Methods for improving treatment outcomes in patients undergoing ultrafiltration |